Intarcia submits ITCA 650 application to FDA
Intarcia Therapeutics has submitted its New Drug Application (NDA) for ITCA 650 to the U.S. Food and Drug Administration. Read More »
Abbvie’s valiparib granted Orphan Drug Designation
AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
FDA accepts BLA for human anti-rabies lgG therapy
Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »
FDA approves Allergan’s RESTASIS MULTIDOSE
The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »
FDA approves XTANDI label update
Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »
New report shows continuing savings of generic drugs
According to a new report released by the 2016 Generic Drug Savings and Access in the United States, generic prescription drugs generated 328 percent increase in annual savings since 2005. Read More »
More prescription coupons, discounts driving up costs, expert argues
Co-pay coupons and discounts offered to consumers ultimately will lead to higher costs across society as they increasingly drive up premiums, according to one leading expert on prescription drugs. Read More »
Coupons for brand-name drugs are misleading, experts say
At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. Read More »
Alerts Sign-up